SCHEMBL9904144

SCHEMBL9904144

Cc1ccc(S(=O)(=O)n2cc(-c3nccc(NC4CCCN(C(=O)OC(C)(C)C)C4)n3)c3cc(-c4c(F)cccc4F)ccc32)cc1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ PIM1 P11309 4/20 0.41
▸ PIM2 Q9P1W9 4/20 0.41
▸ HTR6 P50406 3/20 0.39
▸ BCHE P06276 1/20 0.39
▸ USP30 Q70CQ3 2/20 0.39
▸ SYK P43405 1/20 0.38
▸ HDAC4 P56524 1/20 0.37
▸ HDAC6 Q9UBN7 1/20 0.37
▸ BRD4 O60885 1/20 0.37
▸ PIK3CD O00329 1/20 0.36
▸ SCN9A Q15858 1/20 0.36
▸ CCNK O75909 1/20 0.36
▸ CDK12 Q9NYV4 1/20 0.36
▸ FLT3 P36888 1/20 0.35
▸ PIK3CA P42336 1/20 0.35
▸ BACE1 P56817 1/20 0.35
▸ GFER P55789 1/20 0.35
▸ PARP1 P09874 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9904146 1.00 PIM1 (0.41) PIM1PIM2HTR6BCHEUSP30
SCHEMBL9942535 0.85 CTPS1 (0.37) PIM1PIM2HTR6BCHEUSP30
SCHEMBL9904525 0.84 PIK3CD (0.39) PIM1PIM2HTR6BCHEUSP30
SCHEMBL9904528 0.84 PIK3CD (0.39) PIM1PIM2HTR6BCHEUSP30
SCHEMBL9904658 0.82 PIM1 (0.53) PIM1PIM2USP30HDAC4HDAC6
SCHEMBL9904659 0.82 PIM1 (0.53) PIM1PIM2USP30HDAC4HDAC6
SCHEMBL9942533 0.81 PIM1 (0.38) PIM1PIM2HTR6BCHEUSP30
SCHEMBL9904379 0.78 PIM1 (0.39) PIM1PIM2HTR6BCHEUSP30
SCHEMBL15446264 0.78 PIM1 (0.39) PIM1PIM2HTR6BCHEUSP30
SCHEMBL9942514 0.78 PIM1 (0.39) PIM1PIM2HTR6BCHEUSP30

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9090593-B2 Bicyclic compounds as Pim inhibitors AMGEN INC. (US) 2015-07-28 — — US disclosed
EP-2796456-A1 Bicyclic compounds as Pim inhibitors Amgen Inc. (US) 2014-10-29 — — EP disclosed
US-20140031360-A1 BICYCLIC COMPOUNDS AS PIM INHIBITORS AMGEN INC. (US) 2014-01-30 — — US disclosed
EP-2649065-A1 BICYCLIC COMPOUNDS AS PIM INHIBITORS Amgen Inc. (US) 2013-10-16 — — EP disclosed
WO-2012078777-A1 BICYCLIC COMPOUNDS AS PIM INHIBITORS AMGEN INC. (US) 2012-06-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140031360-A1 BICYCLIC COMPOUNDS AS PIM INHIBITORS PIM1, PIM2, PIM3 PIM1 1/4885PIM2 2/4885HTR6 4372/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback